Abstract
Introduction: Heart failure (HF) is the number one killer in the US and new treatments are needed. Sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA)-2a is a crucial cardiac protein regulating contractility and its downregulation is a molecular hallmark of chronic HF. Its activation underlies β1-adrenergic receptor (AR)-induced cardiac contractility. Agonist-bound β1ARs undergo functional desensitization/internalization due to the actions of βarrestin1 or -2. The two βarrestins are universal receptor adapter proteins and signal transducers thanks to protein scaffolding. Among the cellular processes they can regulate, is protein SUMO (small ubiquitin-like modifier)-ylation, generally increasing protein stability/levels. In the heart, βarrestin1 appears detrimental, whereas βarrestin2 beneficial, for structure and function post-myocardial infarction (MI). Post-MI βarrestin1 knockout mice display elevated SERCA2a activity and better contractility than post-MI wild type (WT) mice. In addition, reduced cardiac SERCA2a SUMOylation is known to underlie its downregulation in HF, decreasing cardiac contractility. Hypothesis: Cardiac β1AR-activated βarrestin2 promotes SERCA2a SUMOylation and activity, thereby regulating contractility. Methods & Results: By studying individual βarrestin knockout heart extracts, we found that βarrestin2, but not βarrestin1, interacts with SERCA2a in the mouse heart in vivo, promoting the latter`s SUMOylation and activity. This interaction is direct, as indicated by pulldown and FRET experiments. In vitro studies in the cardiomyocyte line h9c2 indicate that this interaction is both β1AR-, and β-agonist-specific, and leads to increased Ubc9-dependent SERCA2a SUMOylation, which, in turn, acutely enhances SERCA2a activity. This results in significantly enhanced cardiac function in post-MI HF mice in vivo (Ejection Fraction of WT post-MI mice overexpressing βarrestin2 in the heart vs. control post-MI mice: 46+2.8% vs. 34+2.1%, respectively, p<0.05, n=5). Conclusions: These results suggest that βarrestin2, presumed, like βarrestin1, to decrease cardiac function by desensitizing βARs, may actually (directly) enhance cardiac contractility, thereby opposing βarrestin1 in that regard.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have